Thus, Def appears to effectively disrupt processes central to cancer progression, such as metastasis and chemoresistance, potentially through its multifaceted impact on EGFR, ABCB1, and NDRG1 pathways, in support of our initial hypothesis. The gene discussed is EGFR; the disease is cancer.